Scholarlink

Purpose <p>Whether baseline thyrotropin (TSH) within the reference range predicts thyroid dysfunction in cancer patients remains unclear. We evaluated this association in hospitalized cancer patients with normal baseline thyroid function.</p> Methods <p>This retrospective cohort study (October 2020–September 2025) included 532 cancer patients with normal baseline thyroid function and ≥ 1 follow-up test. Baseline TSH was modeled using restricted cubic splines and categorized as low (&lt; 1.02 mIU/L), optimal (1.02–2.00 mIU/L), or high (&gt; 2.00 mIU/L). Primary outcome was overall thyroid dysfunction; secondary outcomes included clinical dysfunction and mortality. Multivariable Cox models and 365-day restricted mean survival time (RMST) analyses were performed.</p> Results <p>Overall dysfunction occurred in 175 patients (32.9%). Baseline TSH showed a U-shaped association with overall thyroid dysfunction (P for nonlinearity &lt; 0.001), with the lowest risk at 1.02–2.00 mIU/L. Compared with optimal TSH, low TSH (HR 1.90, 95% CI 1.19–3.03) and high TSH (HR 2.22, 95% CI 1.55–3.18) independently predicted increased risk. RMST analysis confirmed 52.5 and 64.6 fewer dysfunction-free days for low and high groups, respectively (both <i>P</i> &lt; 0.001). High TSH predicted clinical dysfunction (HR 1.71, 95% CI 1.03–2.81); low TSH did not. No association was found with mortality.</p> Conclusion <p>In hospitalized cancer patients, baseline TSH within the reference range showed a U-shaped association with incident thyroid dysfunction, with lowest risk at 1.02–2.00 mIU/L. Risk stratification within the conventional reference range may inform personalized monitoring strategies during anticancer treatment.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Baseline TSH within reference range and incident thyroid dysfunction in cancer patients: a retrospective cohort study

  • 期刊论文

  • 发表日期：

    2026年7月27日

查看全文
  • Yin Xia,
  • Bingli Liu,
  • Qian Li,
  • Yunzhu Shen

摘要

Purpose

Whether baseline thyrotropin (TSH) within the reference range predicts thyroid dysfunction in cancer patients remains unclear. We evaluated this association in hospitalized cancer patients with normal baseline thyroid function.

Methods

This retrospective cohort study (October 2020–September 2025) included 532 cancer patients with normal baseline thyroid function and ≥ 1 follow-up test. Baseline TSH was modeled using restricted cubic splines and categorized as low (< 1.02 mIU/L), optimal (1.02–2.00 mIU/L), or high (> 2.00 mIU/L). Primary outcome was overall thyroid dysfunction; secondary outcomes included clinical dysfunction and mortality. Multivariable Cox models and 365-day restricted mean survival time (RMST) analyses were performed.

Results

Overall dysfunction occurred in 175 patients (32.9%). Baseline TSH showed a U-shaped association with overall thyroid dysfunction (P for nonlinearity < 0.001), with the lowest risk at 1.02–2.00 mIU/L. Compared with optimal TSH, low TSH (HR 1.90, 95% CI 1.19–3.03) and high TSH (HR 2.22, 95% CI 1.55–3.18) independently predicted increased risk. RMST analysis confirmed 52.5 and 64.6 fewer dysfunction-free days for low and high groups, respectively (both P < 0.001). High TSH predicted clinical dysfunction (HR 1.71, 95% CI 1.03–2.81); low TSH did not. No association was found with mortality.

Conclusion

In hospitalized cancer patients, baseline TSH within the reference range showed a U-shaped association with incident thyroid dysfunction, with lowest risk at 1.02–2.00 mIU/L. Risk stratification within the conventional reference range may inform personalized monitoring strategies during anticancer treatment.

Graphical Abstract